GlassScriptPhysician profile
Andrea D Zinke
NPI 1346740420
$4,347.28
in general payments reported to CMS, 2019-2025
29 companies · $726 in 2025
The $726 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $855 · 2022: $916 · 2023: $1,260 · 2024: $590 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,063.82 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $739.12 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $299.38 | 2021-2025 | |
| Amgen INC. | $232.85 | 2021-2024 | Prolia, Evenity, Otezla |
| Pfizer INC. | $227.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $216.35 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Exact Sciences Corporation | $196.23 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.31 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $180.93 | 2021-2022 | |
| Abbvie INC. | $167.18 | 2023-2024 | |
| Glaxosmithkline, LLC. | $156.49 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $131.88 | 2021-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.40 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $59.53 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $49.11 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.33 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $39.96 | 2021 | |
| Janssen Pharmaceuticals, INC | $39.94 | 2025 | Spravato |
| Corcept Therapeutics | $37.83 | 2025 | Korlym |
| Organon LLC | $31.41 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.60 | 2022 | |
| Hologic Sales and Service, LLC | $20.10 | 2023 | Aptima |
| Teva Pharmaceuticals USA, INC. | $19.06 | 2021 | |
| Esperion Therapeutics, INC. | $18.98 | 2023 | Nexletol |
| Seqirus USA INC | $17.34 | 2024 | Flucelvax, Fluad |
| Orexo US, INC. | $16.91 | 2023 | Zubsolv |
| Ultragenyx Pharmaceutical INC. | $15.63 | 2021 | |
| Sumitomo Pharma America, INC. | $15.58 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Zinke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.